Structure‐energy‐based predictions and network modelling of RAS opathy and cancer missense mutations
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The Ras/ MAPK syndromes (‘ RAS opathies’) are a class of developmental disorders caused by germline mutations in 15 genes encoding proteins of the Ras/mitogen‐activated protein kinase ( MAPK ) pathway frequently involved in cancer. Little is known about the molecular mechanisms underlying the differences in mutations of the same protein causing either cancer or RAS opathies. Here, we shed light on 956 RAS opathy and cancer missense mutations by combining protein network data with mutational analyses based on 3D structures. Using the protein design algorithm FoldX, we predict that most of the missense mutations with destabilising energies are in structural regions that control the activation of proteins, and only a few are predicted to compromise protein folding. We find a trend that energy changes are higher for cancer compared to RAS opathy mutations. Through network modelling, we show that partly compensatory mutations in RAS opathies result in only minor downstream pathway deregulation. In summary, we suggest that quantitative rather than qualitative network differences determine the phenotypic outcome of RAS opathy compared to cancer mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 1×
“In general, all RASopathie mutations are germline, while 90% of cancer mutations are somatic (Futreal et al , 2004).”
BackgroundThe FoldX web server: an online force field
Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F., & Serrano, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki387 · Cited by 2,759
Self-citationThe Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Guerois, R., Nielsen, J. E., & Serrano, L. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00442-4 · Cited by 1,728 · cited 2×
“FoldX (http://foldx.crg.es/) is a computer algorithm that allows the calculation of interaction energies contributing to the stability of proteins and protein complexes (Guerois et al , 2002; Schymko-witz et al , 2005).”
BackgroundMethodSelf-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583 · cited 2×
“RASopathies are a group of germline developmental disorders of the Ras-MAPK pathway, such as Noonan, cardio-facio-cutaneous (CFC), Costello and LEOPARD syndromes (Tartaglia & Gelb, 2005; Bentires-Alj et al , 2006; Schubbert et al , 2007b; Aoki et al , 2008; Tartaglia et al , 2010).”
BackgroundThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 1×
“The crystal structure of Ras has been solved in complex with the GAP domain of RASA1 (pdb entry 1WQ1) (Scheffzek et al , 1997), the Ras-binding domain (RBD) of RAF1 (pdb entry 1GUA) (Nassar et al , 1996), and in complex with SOS1 (see before, pdb entry 1XD2) (Sondermann et al , 2004).”
BackgroundLarge-scale analysis of the human and mouse transcriptomes
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., Orth, A. P., Vega, R. G., Sapinoso, L. M., Moqrich, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012025199 · Cited by 1,466
Structure of a c-Cbl–UbcH7 Complex
Zheng, N., Wang, P., Jeffrey, P. D., & Pavletich, N. P. (2000) · Cell · doi:10.1016/s0092-8674(00)00057-x · Cited by 839 · cited 1×
“The crystal structure of the trimeric complex of the Cbl_N, Cbl_N2, Cbl_N3 and zf_C3HC4 domains of CBL in complex with the E2 domain of UbcH7 and a peptide of the ZAP-70 receptor (pdb entry 1FBV) (Zheng et al , 2000).”
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605 · cited 1×
“Most mutants described result in up-regulating the RAS-RAF-ERK-MAPK-kinase cascade (Tartaglia & Gelb, 2005; Rodriguez-Viciana et al , 2006; Roberts et al , 2007; Tartaglia et al , 2007; Pandit et al , 2007; Sarkozy et al , 2009; Lepri et al , 2011; Andreadi et al , 2012) and are found in 15 genes:…”
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415 · cited 1×
“…only little insights into the quantitative relation between the impact of a mutation and its structural localisation and disease severity have been achieved for proteins involved in RASopathies and/or cancer (Keilhack et al , 2005; Tartaglia et al , 2006; Cirstea et al , 2010; Molzan et al , 2010).”
Cited by
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
PremPS: Predicting the impact of missense mutations on protein stability
Chen, Y., Lu, H., Zhang, N., Zhu, Z., Wang, S., & Li, M. (2020) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008543 · Cited by 260
Hot-spot analysis for drug discovery targeting protein-protein interactions
Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105
“Detailed understanding of the behavior of a protein interaction network in pathological conditions is especially critical for complex diseases such as cancer or rare conditions related to the malfunction of the Ras signaling pathway (RASopathies) [82].”
BackgroundUsmanova, D. R., Bogatyreva, N. S., Ariño Bernad, J., Eremina, A. A., Gorshkova, A. A., Kanevskiy, G. M., Lonishin, L. R., Meister, A. V., Yakupova, A. G., Kondrashov, F. A., et al. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty340 · Cited by 93
(2023) · doi:10.1016/j.str.2023.04.007 · Cited by 6
Deciphering GB1’s Single Mutational Landscape: Insights from MuMi Analysis
Guclu, T. F., Atilgan, A. R., & Atilgan, C. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c04916
Metadata
- Authors
- Kiel, C., & Serrano, L.
- Venue
- Molecular Systems Biology
- Published
- 2014-05
- Volume
- 10
- Issue
- 5
- Pages
- 727-727
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W2101701152
- Cited by
- 65
- References
- 18
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.